Sign up for Table of Contents Alerts.

Email this page

Print this page

Extra Views

USP22, an hSAGA subunit and potential cancer stem cell marker, reverses the polycomb-catalyzed ubiquitylation of histone H2A

Xiao-yong Zhang, Harla Pfeiffer, Alan Thorne and Steven B. McMahon

Purchase article for $19

Subscribe to this journal for $129/year

Initial studies of the mammalian hSAGA transcriptional coactivator complex identified the acetyltransferase hGCN5/PCAF as the only known enzymatic subunit. Recently we demonstrated that the ubiquitin hydrolase USP22 comprises a second enzymatic subunit of hSAGA, and that is required for activator-driven transcription. USP22 is expressed with polycomb ubiquitin ligases in an 11 gene signature that defines therapy-resistant tumors. At the biochemical level, these Polycomb proteins function as global transcriptional repressors by catalyzing the ubiquitylation of histone H2A. In yeast, the USP22 homolog functions as a transcriptional coactivator by removing ubiquitin from a distinct core histones, H2B. Given that USP22 is expressed in cancer as part of an 11 gene signature that includes transcriptional repressors which ubiquitylate H2A, it seemed possible that USP22 might activate transcription in part via the deubiquitylation of this same substrate. As reported here, biochemical analysis of the substrate specificity of USP22 reveals that it deubiquitylates histone H2A in addition to H2B. This finding supports a model in which the H2A ubiquitin hydrolase USP22 is coordinately expressed with Polycomb H2A ubiquitin ligases in order that the transcription of certain critical transforming genes be maintained in the face of the global repression mediated by Polycomb.

Authors

Xiao-yong Zhang

Kimmel Cancer Center; Philadelphia, PA

Harla Pfeiffer

Kimmel Cancer Center; Philadelphia, PA

Alan Thorne

University of Portsmouth; Portsmouth UK

Steven B. McMahon

Kimmel Cancer Center; Philadelphia, PA

Purchase article for $19

Subscribe to this journal for $129/year